Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
Jong‐Hoon Lee(Chonnam National University Hospital), M. Miles Braun(Center for Biologics Evaluation and Research), Sharon K. Gershon(Center for Biologics Evaluation and Research), Nancy R. Slifman(Center for Biologics Evaluation and Research), William D. Schwieterman(United States Food and Drug Administration), Evelyne T. Edwards(Center for Biologics Evaluation and Research), John N. Udall(North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition), Jeffrey Siegel(Center for Drug Evaluation and Research), S Brown(Center for Biologics Evaluation and Research), Robert P. Wise(Center for Biologics Evaluation and Research)
Cited by 448
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
|PubMed|2003|397
<i>Listeria monocytogenes</i> infection as a complication of treatment with tumor necrosis factor α–neutralizing agents
|Arthritis & Rheumatism|2003|387